PCI Pharma Services (PCI) has unveiled plans to invest more than $20 million to support biologic medicines and advanced injectable delivery forms. PCI will begin by expanding its biotech clinical and commercial packaging and release testing capability at its Center of Excellence in Philadelphia. Part of the investment will also be used to expand cold chain capacity at numerous global locations to further support its existing biotech infrastructure.
 
The latest investment will include capacity expansion for cutting edge technologies for the labeling and assembly of state-of-the-art safety syringes, autoinjector and pen devices with integrated high speed cartoning, in-line serialization, as well as furthering its expansive onsite cold chain storage. 
 
PCI’s injectable delivery form capabilities include ampoules, vials, cartridges and standard prefilled syringes, as well as advanced safety syringes, autoinjectors and pen devices with services including both simple and complex kitting for clinical and commercial applications. In handling biologic medicines, PCI maintains a comprehensive cold chain and ultra cold chain portfolio with temperature ranges from refrigerated 2-8°C, frozen -20°C, -40°C, -80°C and cryogenic temperatures of -196°C for advanced medicinal therapeutic products (ATMP), including cell and gene therapy medicines.
 
“I am pleased to share this news regarding our continued investment to support the needs of our biotech customers,” said Salim Haffar, chief executive officer, PCI. “It’s estimated that close to 40 percent of all medicines in pipeline development are biologic, and amazing new therapies are being developed and commercialized every day. With the development and commercialization wave of biologic medicines, the market is rapidly evolving. We are proud to be the partner of choice for drug development companies as they look to outsource these specialized requirements for clinical and commercial packaging.”